Physics

Booster dose

Internal medicine

Pediatrics

Adverse effect

Virus

Disease

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Astronomy

Virology

Vaccination

Booster (rocketry)

Adverse Event Reporting System

Titer

Medicine

MMWR Morbidity and Mortality Weekly Report

approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.*The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous).These booster authorizations apply to all three COVID-19 vaccines used in the United States (1-3).† The Advisory Committee on Immunization Practices (ACIP) recommended preferential use of an mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer-BioNTech]) for a booster, even for persons who received the Ad26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine for their single-dose primary series.§ To characterize the safety of COVID-19 vaccine boosters among persons aged ≥18 years during September 22, 2021-February 6, 2022, CDC reviewed adverse events and health impact assessments following receipt of a booster that were reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA.Among 721,562 v-safe registrants aged ≥18 years who reported receiving a booster, 88.8% received homologous COVID-19 mRNA vaccination.Among registrants who reported a homologous COVID-19 mRNA booster dose, systemic reactions were less frequent following the booster (58.4% [Pfizer-BioNTech] and 64.4% [Moderna], respectively) than were those following dose 2 (66.7% and 78.4%, respectively).The adjusted odds of reporting a systemic reaction were higher following a Moderna COVID-19 vaccine booster, irrespective of the vaccine received * https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic† The FDA has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous).These booster authorizations apply to all three COVID-19 vaccines used in the United States: 1) Pfizer-BioNTech COVID-19 vaccine ≥5 months after dose 2 for persons aged ≥12 years, 2) Moderna COVID-19 vaccine ≥5 months after dose 2 for persons aged ≥18 years, and 3) Janssen COVID-19 vaccine ≥2 months after a single dose for persons aged ≥18 years.§ https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19vaccines-us.html

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022